AlphaStocks
4.8
Weak

Jazz Pharmaceuticals plc (JAZZ)

Health Care / Pharmaceuticals

S&P MidCap 400

$188.33

Below average on several measures. Research carefully.

Weak

Score based on 4 of 5 models — moderate confidence

#622out of 1127 in Health Care

Is Jazz Pharmaceuticals plc a Good Investment in 2026?

Jazz Pharmaceuticals plc (JAZZ) scores 4.8 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates Jazz Pharmaceuticals plc as Attractive (5/9). However, the Greenblatt Magic Formula model rates it Caution — Bottom half (rank 93%). Jazz Pharmaceuticals plc currently trades above its estimated fair value of $154, suggesting limited upside at current prices. Jazz Pharmaceuticals plc ranks #622 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-8.5Market Cap11B

Estimated Fair Value

$154.3522% above

Trading slightly above estimated fair value.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Caution

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Attractive

Growth rate vs price (PEG)

Greenblatt

Caution

Bottom half (rank 93%)

Frequently Asked Questions

Is Jazz Pharmaceuticals plc (JAZZ) a good investment?
Based on AlphaStocks' composite analysis, Jazz Pharmaceuticals plc (JAZZ) scores 4.8 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trading slightly above estimated fair value.
What is Jazz Pharmaceuticals plc's Piotroski F-Score?
Jazz Pharmaceuticals plc's Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is JAZZ overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $154, JAZZ appears overvalued. The stock currently trades 22% above its estimated fair value. Trading slightly above estimated fair value.
How does JAZZ compare to other Health Care stocks?
Jazz Pharmaceuticals plc ranks #622 out of 1127 stocks in the Health Care sector, placing it in the top 55% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about JAZZ?
AlphaStocks evaluates JAZZ using five proven investment models. Piotroski: Attractive; Buffett: Caution; Graham: Caution; Lynch: Attractive; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 4.8/10.

Similar Stocks

PARRFTIAZN

Compare JAZZ with

JAZZ vs PARRJAZZ vs FTIJAZZ vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer